Abstract
Post-transplant diabetes mellitus (PTDM) reduces allograft and recipient life span. Polygenic risk scores (PRSs) show robust association with greater risk of developing type 2 diabetes (T2D). We examined the association of PTDM with T2D PRS in liver recipients (n = 1,581) and their donors (n = 1,555), and kidney recipients (n = 2,062) and their donors (n = 533). Recipient T2D PRS was associated with pre-transplant T2D and the development of PTDM. T2D PRS in liver donors, but not in kidney donors, was an independent risk factor for PTDM development. The inclusion of a combined liver donor and recipient T2D PRS significantly improved PTDM prediction compared with a model that included only clinical characteristics: the area under the curve (AUC) was 67.6% (95% confidence interval (CI) 64.1–71.1%) for the combined T2D PRS versus 62.3% (95% CI 58.8–65.8%) for the clinical characteristics model (P = 0.0001). Liver recipients in the highest quintile of combined donor and recipient T2D PRS had the greatest risk of PTDM, with an odds ratio of 3.22 (95% CI 2.07–5.00) (P = 1.92 × 10−7) compared with those in the lowest quintile. In conclusion, T2D PRS identifies transplant candidates with high risk of PTDM for which pre-emptive diabetes management and donor selection may be warranted.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Upon request, the authors can provide the deidentified genetic and clinical datasets that were used for the T2D PRS analysis. GWAS summary statistics are available in the GWAS Catalog (https://www.ebi.ac.uk/gwas) under GCST90091503 and GCST90091504. Organ donor-specific GWG datasets were generated using Human Subjects Exemption, and data use agreements would not allow the transfer of donor-level genetic datasets. The authors will collaborate with interested investigators and run scripts against relevant donor-level and recipient-level data. The collaborative projects will be initiated within 1 month of request being made by e-mail to baoli@pennmedicine.upenn.edu. Source data are provided with this paper.
Code availability
Publicly available analysis tools were employed as described in the Methods, and no custom code was used for the analysis of data.
References
Luan, F. L., Steffick, D. E. & Ojo, A. O. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 91, 334–341 (2011).
First, M. R., Dhadda, S., Croy, R., Holman, J. & Fitzsimmons, W. E. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. Transplantation 96, 58–64 (2013).
Jenssen, T. & Hartmann, A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat. Rev. Endocrinol. 15, 172–188 (2019).
Sharif, A. et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am. J. Transplant. 14, 1992–2000 (2014).
Pham, P. T., Sidhu, H. S., Pham, P. M. & Pham, P. C. in Endotext (eds Feingold K. R., et al.) (MDText.com, 2000).
Jiménez-Pérez, M., González-Grande, R., Omonte Guzmán, E., Amo Trillo, V. & Rodrigo López, J. M. Metabolic complications in liver transplant recipients. World J. Gastroenterol. 22, 6416–6423 (2016).
Roccaro, G. A. et al. Sustained posttransplantation diabetes is associated with long-term major cardiovascular events following liver transplantation. Am. J. Transplant. 18, 207–215 (2018).
VanWagner, L. B. et al. High early cardiovascular mortality after liver transplantation. Liver Transpl. 20, 1306–1316 (2014).
Cosio, F. G. et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 67, 2415–2421 (2005).
Valderhaug, T. G. et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 54, 1341–1349 (2011).
Ling, Q. et al. The tacrolimus-induced glucose homeostasis imbalance in terms of the liver: from bench to bedside. Am. J. Transplant. 20, 701–713 (2020).
Wallia, A., Illuri, V. & Molitch, M. E. Diabetes care after transplant: definitions, risk factors, and clinical management. Med Clin. North Am. 100, 535–550 (2016).
Johnston, O., Rose, C. L., Webster, A. C. & Gill, J. S. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J. Am. Soc. Nephrol. 19, 1411–1418 (2008).
Sharif, A. & Baboolal, K. Risk factors for new-onset diabetes after kidney transplantation. Nat. Rev. Nephrol. 6, 415–423 (2010).
Langenberg, C. & Lotta, L. A. Genomic insights into the causes of type 2 diabetes. Lancet 391, 2463–2474 (2018).
Udler, M. S., McCarthy, M. I., Florez, J. C. & Mahajan, A. Genetic risk scores for diabetes diagnosis and precision medicine. Endocr. Rev. 40, 1500–1520 (2019).
Han, H.-S., Kang, G., Kim, J. S., Choi, B. H. & Koo, S.-H. Regulation of glucose metabolism from a liver-centric perspective. Exp. Mol. Med 48, e218 (2016).
Rui, L. Energy metabolism in the liver. Compr. Physiol. 4, 177–197 (2014).
Gerich, J. E., Meyer, C., Woerle, H. J. & Stumvoll, M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24, 382–391 (2001).
Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005–D1012 (2019).
Sullivan, K. M. & Susztak, K. Unravelling the complex genetics of common kidney diseases: from variants to mechanisms. Nat. Rev. Nephrol. 16, 628–640 (2020).
Povysil, G. et al. Rare-variant collapsing analyses for complex traits: guidelines and applications. Nat. Rev. Genet. 20, 747–759 (2019).
Wand, H. et al. Improving reporting standards for polygenic scores in risk prediction studies. Nature 591, 211–219 (2021).
Tam, V. et al. Benefits and limitations of genome-wide association studies. Nat. Rev. Genet. 20, 467–484 (2019).
Chand, S., McKnight, A. J. & Borrows, R. Genetic polymorphisms and kidney transplant outcomes. Curr. Opin. Nephrol. Hypertens. 23, 605–610 (2014).
Benson, K. A., Maxwell, A. P. & McKnight, A. J. A HuGE review and meta-analyses of genetic associations in new onset diabetes after kidney transplantation. PLoS ONE 11, e0147323 (2016).
Quteineh, L. et al. CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. Pharmacogenomics J. 17, 69–75 (2017).
Lancia, P. et al. Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus. Pediatr. Nephrol. 33, 1045–1055 (2018).
McCaughan, J. A., McKnight, A. J. & Maxwell, A. P. Genetics of new-onset diabetes after transplantation. J. Am. Soc. Nephrol. 25, 1037–1049 (2014).
Oetting, W. S. et al. Genetic variants associated with immunosuppressant pharmacokinetics and adverse effects in the DeKAF genomics genome-wide association studies. Transplantation 103, 1131–1139 (2019).
Saigi-Morgui, N. et al. Genetic and clinic predictors of new onset diabetes mellitus after transplantation. Pharmacogenomics J. 19, 53–64 (2019).
Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat. Genet. 50, 1505–1513 (2018).
Peláez-Jaramillo, M. J., Cárdenas-Mojica, A. A., Gaete, P. V. & Mendivil, C. O. Post-liver transplantation diabetes mellitus: a review of relevance and approach to treatment. Diabetes Ther. 9, 521–543 (2018).
Hecking, M., Sharif, A., Eller, K. & Jenssen, T. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transpl. Int. 34, 27–48 (2021).
Peer, N., Balakrishna, Y. & Durao, S. Screening for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 5, CD005266 (2020).
Kautzky-Willer, A., Harreiter, J. & Pacini, G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr. Rev. 37, 278–316 (2016).
Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat. Genet. 52, 680–691 (2020).
Halden, T. A. S. et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes. Diabetes Care 39, 617–624 (2016).
Ekstrand, A. V., Eriksson, J. G., Grönhagen-Riska, C., Ahonen, P. J. & Groop, L. C. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. Transplantation 53, 563–569 (1992).
Ali, I. H. et al. Incidence and risk factors for post-renal transplant diabetes mellitus. Transplant. Proc. 43, 568–571 (2011).
Depczynski, B., Daly, B., Campbell, L. V., Chisholm, D. J. & Keogh, A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet. Med 17, 15–19 (2000).
Kang, E. S. et al. Association of common type 2 diabetes risk gene variants and posttransplantation diabetes mellitus in renal allograft recipients in Korea. Transplantation 88, 693–698 (2009).
Rodrigo, E. et al. New-onset diabetes after kidney transplantation: risk factors. J. Am. Soc. Nephrol. 17, S291–S295 (2006).
Montori, V. M. et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 25, 583–592 (2002).
Castedal, M., Skoglund, C., Axelson, C. & Bennet, W. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation. Scand. J. Gastroenterol. 53, 741–747 (2018).
Wissing, K. M. et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. Am. J. Transplant. 18, 1726–1734 (2018).
Vanrenterghem, Y. et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 91, 976–983 (2011).
Hecking, M. et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J. Am. Soc. Nephrol. 23, 739–749 (2012).
Jenssen, T. & Hartmann, A. Emerging treatments for post-transplantation diabetes mellitus. Nat. Rev. Nephrol. 11, 465–477 (2015).
Shaked, A. et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. Am. J. Transplant. 19, 1397–1409 (2019).
Feng, S. et al. Efficacy and safety of immunosuppression withdrawal in pediatric liver transplant recipients: moving towards personalized management. Hepatology 73, 1985–2004 (2021).
Jucaud, V. et al. Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients. Hepatology 69, 1273–1286 (2019).
O’Leary, J. G. et al. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am. J. Transplant. 15, 1003–1013 (2015).
Porrini, E. L. et al. Clinical evolution of post-transplant diabetes mellitus. Nephrol. Dial. Transplant. 31, 495–505 (2016).
Li, Y. R. et al. Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies. Genome Med. 7, 90 (2015).
International Genetics & Translational Research in Transplantation Network (iGeneTRAiN). Design and implementation of the International Genetics and Translational Research in Transplantation Network. Transplantation 99, 2401–2412 (2015).
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet 81, 559–575 (2007).
Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
Sudmant, P. H. et al. An integrated map of structural variation in 2,504 human genomes. Nature 526, 75–81 (2015).
The Genome of the Netherlands Consortium. Whole-genome sequence variation, population structure and demographic history of the Dutch population. Nat. Genet. 46, 818–825 (2014).
Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179–181 (2011).
Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906–913 (2007).
Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
Choi, S. W., Mak, T. S.-H. & O’Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. Nat. Protoc. 15, 2759–2772 (2020).
Acknowledgements
Funding for this study was received from the Fred and Suzanne Biesecker Pediatric Liver Center at Children’s Hospital of Philadelphia (A.S.), Gift-of-Life Organ Procurement Organization (A.S.), and National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) grant no. U01AI152960-01 (A.S. and B.J.K.).
Author information
Authors and Affiliations
Contributions
A.S., B.-L.L. and B.J.K. contributed to the design, analysis and writing of this study. A.Z., C.E.F., H.G., A.K.I., P.A.J., W.S.O., M.N., E.V.L. and S.K.A. contributed to data collection and literature review. A.S., B.-L.L., B.J.K., K.M.O., G.T., G.K., S.K.A., A.K.I., P.A.J., W.S.O., J.T., M.N. and E.V.L. contributed samples and phenotypes. A.S., B.-L.L., W.G., B.J.K., M.N. and E.V.L. contributed to, advised on and supervised statistical analysis. A.S., B.-L.L., K.M.O., S.K.A. and B.J.K. composed and revised the manuscript drafts. All co-authors read and approved the final manuscript for submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Medicine thanks Trond Jenssen, Adnan Sharif and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Anna Maria Ranzoni, in collaboration with the Nature Medicine team.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 ROC curve for the model to predict T2D for the Penn and Baylor combined liver transplant cohorts.
The probability of the PRS model to predict the development of T2D in the post-transplant population is similar to what was shown for T2D genetic predictors in the general population. AUROC curve for the multivariate logistic regression model to predict PTDM in recipients for the Penn and Baylor combined liver transplant cohorts (cases n=321, controls n=835) was depicted. The test statistics for each terms included in the multivariate logistic regression model were listed in Table 3. This multivariate model had AUC of 67.6% (95%CI: 64.1%–71.1%) at a threshold of 0.514. The negative and positive predictive values were 81.3 and 42.5 respectively, assuming 28% prevalence.
Supplementary information
Source data
Source Data Fig. 1
Statistical source data.
Source Data Fig. 2
Statistical source data.
Rights and permissions
About this article
Cite this article
Shaked, A., Loza, BL., Van Loon, E. et al. Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes. Nat Med 28, 999–1005 (2022). https://doi.org/10.1038/s41591-022-01758-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01758-7